ScinoPharm Taiwan Ltd
ScinoPharm Taiwan, Ltd., together with its subsidiaries, research and develops, produces, and sells active pharmaceutical ingredients (API) to pharmaceutical companies in Taiwan, rest of Asia, Europe, the America, and internationally. The company provides small molecular drugs, protein drugs, complex natural molecules and derivatives, synthesis services for biochemistry molecules, such as peptide… Read more
ScinoPharm Taiwan Ltd (1789) - Total Liabilities
Latest total liabilities as of September 2025: NT$1.32 Billion TWD
Based on the latest financial reports, ScinoPharm Taiwan Ltd (1789) has total liabilities worth NT$1.32 Billion TWD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
ScinoPharm Taiwan Ltd - Total Liabilities Trend (2007–2024)
This chart illustrates how ScinoPharm Taiwan Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
ScinoPharm Taiwan Ltd Competitors by Total Liabilities
The table below lists competitors of ScinoPharm Taiwan Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ningbo Shimao Energy Co.Ltd
SHG:605028
|
China | CN¥180.06 Million |
|
Hindustan Foods Limited
NSE:HNDFDS
|
India | ₹17.53 Billion |
|
Fibra Inn
MX:FINN13
|
Mexico | MX$4.44 Billion |
|
Goody Science & Technology Co Ltd
SHE:002694
|
China | CN¥1.12 Billion |
|
Rukun Raharja Tbk
JK:RAJA
|
Indonesia | Rp3.48 Trillion |
|
Hamilton Thorne Ltd
PINK:HTLZF
|
USA | $43.40 Million |
|
Neo Performance Materials Inc
PINK:NOPMF
|
USA | $248.37 Million |
Liability Composition Analysis (2007–2024)
This chart breaks down ScinoPharm Taiwan Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.85 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ScinoPharm Taiwan Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ScinoPharm Taiwan Ltd (2007–2024)
The table below shows the annual total liabilities of ScinoPharm Taiwan Ltd from 2007 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$1.42 Billion | +4.40% |
| 2023-12-31 | NT$1.36 Billion | -7.12% |
| 2022-12-31 | NT$1.46 Billion | +23.81% |
| 2021-12-31 | NT$1.18 Billion | -10.42% |
| 2020-12-31 | NT$1.32 Billion | -6.88% |
| 2019-12-31 | NT$1.41 Billion | -30.12% |
| 2018-12-31 | NT$2.02 Billion | -11.38% |
| 2017-12-31 | NT$2.28 Billion | -10.61% |
| 2016-12-31 | NT$2.56 Billion | +8.06% |
| 2015-12-31 | NT$2.36 Billion | +18.73% |
| 2014-12-31 | NT$1.99 Billion | +8.18% |
| 2013-12-31 | NT$1.84 Billion | +45.06% |
| 2012-12-31 | NT$1.27 Billion | +37.83% |
| 2011-12-31 | NT$920.78 Million | +48.28% |
| 2010-12-31 | NT$620.97 Million | -54.07% |
| 2009-12-31 | NT$1.35 Billion | -41.76% |
| 2008-12-31 | NT$2.32 Billion | -25.21% |
| 2007-12-31 | NT$3.10 Billion | -- |